Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 1:11 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 409–432 of 6,190 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Medication Group Clear all

Conditions: Multiple Sclerosis, Relapsing-Remitting
Interventions: Blood Draw, Lumbar Puncture; Procedure
Lead sponsor: Providence Health & Services; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2023
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Hypertension
Interventions: valsartan+amlodipine; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years and older
Enrollment: 1,293 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Pregnancy, Migraine, Headache, Postpartum, Depression, Anxiety
Interventions: external Trigeminal Nerve Stimulation; Device
Lead sponsor: Cefaly Technology; Industry
Eligibility: 18 Years to 44 Years · Female only
Enrollment: 550 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 1
States / cities: Darien, Connecticut

Conditions: Atopic Dermatitis
Interventions: Pimecrolimus Cream, 1%, Elidel® (pimecrolimus) Cream, Placebo of Pimecrolimus Cream, 1%; Drug
Lead sponsor: Glenmark Pharmaceuticals Ltd. India; Industry
Eligibility: 12 Years and older
Enrollment: 755 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 27
States / cities: Hot Springs, Arkansas • Little Rock, Arkansas • Anaheim, California + 19 more

Conditions: Pneumococcal Immunization, Healthy Volunteers
Interventions: PCV21 vaccine, 20vPCV licensed vaccine; Biological
Lead sponsor: Sanofi; Industry
Eligibility: 42 Days to 89 Days
Enrollment: 2,195 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 14
States / cities: Fayetteville, Arkansas • Huntington Park, California • Los Angeles, California + 10 more

Conditions: Type 2 Diabetes, Type 2 Diabetes Mellitus (T2DM), Type 2 Diabetes (T2D)
Interventions: Augmented Initial Type 2 Diabetes Care; Behavioral
Lead sponsor: Kaiser Permanente; Other
Eligibility: 18 Years to 74 Years
Enrollment: 204 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Pleasanton, California

Conditions: Asthma
Interventions: Multi-Component Technology Based Intervention; Behavioral
Lead sponsor: Wayne State University; Other
Eligibility: 18 Years to 29 Years
Enrollment: 192 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Pancreatic Cancer Metastatic, Pancreatic Adenocarcinoma Metastatic
Interventions: Botensilimab, Balstilimab, Chloroquine Phosphate, Celecoxib, Nab paclitaxel, Gemcitabine, Cisplatin; Drug
Lead sponsor: HonorHealth Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 1
States / cities: Scottsdale, Arizona

Conditions: Breast Cancer
Interventions: Talazoparib, Sacituzumab Govitecan; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older · Female only
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2029
U.S. locations: 3
States / cities: Boston, Massachusetts

Conditions: Atopic Dermatitis
Interventions: Not listed
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 480 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Hepatic Impairment, Healthy Volunteers
Interventions: Repotrectinib; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 3
States / cities: Miami Lakes, Florida • Orlando, Florida • San Antonio, Texas

Conditions: Pneumonia
Interventions: Pre and post vaccination titers; Other
Lead sponsor: George Washington University; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Sarcopenia
Interventions: Resistance Training Intervention, Active Control Group; Behavioral
Lead sponsor: University of Rhode Island; Other
Eligibility: 65 Years to 84 Years · Female only
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Kingston, Rhode Island

Conditions: SARS-CoV-2 Infection
Interventions: BTL-TML-COVID, Placebo; Drug
Lead sponsor: Beech Tree Labs, Inc.; Industry
Eligibility: 40 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Draper, Utah

Conditions: Moderate Hepatic Impairment, Severe Hepatic Impairment, Healthy Volunteers
Interventions: Lorlatinib; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 3
States / cities: Tustin, California • Tampa, Florida • Saint Paul, Minnesota

Conditions: Major Depressive Disorder
Interventions: Memantine; Drug
Lead sponsor: Mclean Hospital; Other
Eligibility: 55 Years to 89 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Belmont, Massachusetts

Conditions: Venous Thromboembolism
Interventions: Education; Behavioral
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Glioblastoma Multiforme
Interventions: Dichloroacetate (DCA), Genotype; Drug · Genetic
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 80 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 2
States / cities: Baltimore, Maryland • Winston-Salem, North Carolina

Conditions: Inflammatory Bowel Diseases
Interventions: Health Coaching, Surveys; Behavioral · Other
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Hypertension, Retinal Disorder, Cognitive Impairment
Interventions: Not listed
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 234 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2020
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Lupus Erythematosus, Systemic
Interventions: Cenerimod, Placebo; Drug
Lead sponsor: Viatris Innovation GmbH; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 470 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 22
States / cities: Huntington Park, California • Aurora, Colorado • Clearwater, Florida + 16 more

Conditions: Diabetes Mellitus, Type 2, Insulin Resistance
Interventions: HydraSolve T2D™; Device
Lead sponsor: Medality Medical; Industry
Eligibility: 22 Years to 75 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Irritable Bowel Syndrome
Interventions: IBS Group, Healthy Control Group; Other
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2025
U.S. locations: 2
States / cities: Philadelphia, Pennsylvania • Villanova, Pennsylvania

Conditions: HIV Infections
Interventions: VSV-Indiana HIV gag vaccine, Placebo injection (normal saline); Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2011
U.S. locations: 4
States / cities: San Francisco, California • Decatur, Georgia • Philadelphia, Pennsylvania + 1 more

Search by objective public record fields.

Measurement of Relaxin Peptide in Multiple Sclerosis (MS)

One Year Study to Evaluate the Safety of the Combination of Valsartan and Amlodipine in Patients With Hypertension

External Trigeminal Nerve Stimulation for Migraine Treatment in Pregnancy

Study of Generic Pimecrolimus Cream, 1% in the Treatment of Mild to Moderate Atopic Dermatitis

Lot-to-lot Consistency Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From 2 Months of Age

Population Health Management for KPNC Members With Newly Diagnosed Diabetes: A Randomized Trial of a Proactive and Augmented Initial Care Strategy

Detroit Young Adult Asthma Project

The Seven Trial: Exploiting the Unfolded Protein Response

Study to Evaluate Sacituzumab Govitecan in Combination With Talazoparib in Patients With Metastatic Breast Cancer.

Clinical vs. Anecdotal Evidence - Pediatric Atopic Dermatitis

A Study to Assess the Drug Levels of Repotrectinib in Healthy Participants and Participants With Moderate and Severe Hepatic Impairment

A Study To Examine Serologic Response In Hospitalized Patients Receiving Polyvalent Pneumococcal Vaccine

Effects of a Resistance Training Program in Older Women With Sarcopenia

A Study in Adults to Test the Effects of Low Dose Thimerosal on Symptoms of COVID-19

A Study to Learn About the Study Medicine (Called Lorlatinib) in People With Liver Dysfunction

Treatment Resistant Geriatric Depression in Primary Care

Evaluation of Venous Thromboembolism (VTE) Prophylaxis in Medically Ill Patients

Trial of Dichloroacetate (DCA) in Glioblastoma Multiforme (GBM)

Health Coaching as a Tool for Improving Medication Adherence in Adult Patients With Inflammatory Bowel Disease

DETECT and Retinal Outcomes in Hypertension

A Research Study to Evaluate the Effects of a New Oral Medicine Called Cenerimod in Adults With Systemic Lupus Erythematosus

Evaluation of Intra-Abdominal Fat Extraction Using HydraSolve T2D™ in Obese Subjects With Type 2 Diabetes

Pilot Study of the Physiological Effects of an Integrative Medicine Approach in Irritable Bowel Syndrome

Evaluating the Safety of and Immune Response to the VSV-Indiana HIV Vaccine in Healthy, HIV-Uninfected Adults